Back to today’s briefing

Story perspectives

FDA to Review Peptide Reclassification, Reversing Biden Decision

7/22/2026

26 6 Full Breakdown

Summary

Story summary

Food and Drug Administration (FDA) will meet July 23-24 to review reclassifying seven peptides for pharmacy compounding, reversing a 2023 Biden decision.
The Pharmacy Compounding Advisory Committee added eight temporary voting members over concerns about prior members’ industry ties.
More than 20 million doses of the peptides were dispensed in the past eight years, showing a multibillion-dollar market.

1 of 1

Story summary

Food and Drug Administration (FDA) will meet July 23-24 to review reclassifying seven peptides for pharmacy compounding, reversing a 2023 Biden decision.
The Pharmacy Compounding Advisory Committee added eight temporary voting members over concerns about prior members’ industry ties.
More than 20 million doses of the peptides were dispensed in the past eight years, showing a multibillion-dollar market.